HOUSTON, TX, June 13, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced that its second generation (Gen-2), 15 milliamp (mA) neurostimulation device has been granted regulatory approval by the Brazilian Health Regulatory Agency, a regulatory body of the Brazilian government responsible for approving new drugs and medical devices. Mark White, CEO of Nexalin Technology, stated, "We are pleased to announce approval to sell our Gen-2 neurostimula ...

HOUSTON, TX, June 13, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the "Company" or "Nexalin") (NASDAQ:NXL, NXLIW))) today announced that its second generation (Gen-2), 15 milliamp (mA) neurostimulation device has been granted regulatory approval by the Brazilian Health Regulatory Agency, a regulatory body of the Brazilian government responsible for approving new drugs and medical devices. Mark White, CEO of Nexalin Technology, stated, "We are pleased to announce approval to sell our Gen-2 neurostimul ...

HOUSTON, TX, June 04, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the "Company" or "Nexalin") (Nasdaq: NXL; NXLIW) announced today that it will be participating in the Spring MicroCap Rodeo Conference, that will be held on Thursday, June 6, 2024 in New York City. Mark White, Chief Executive Officer of Nexalin is scheduled to present at 10:00 a.m. Eastern Time on Thursday, June 6th. The presentation will be webcast live and available at https://www.webcaster4.com/Webcast/Page/3045/50684 as well as on ...

HOUSTON, TX, June 04, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the "Company" or "Nexalin") (Nasdaq: NXL; NXLIW) announced today that it will be participating in the Spring MicroCap Rodeo Conference, that will be held on Thursday, June 6, 2024 in New York City. Mark White, Chief Executive Officer of Nexalin is scheduled to present at 10:00 a.m. Eastern Time on Thursday, June 6th. The presentation will be webcast live and available at https://www.webcaster4.com/Webcast/Page/3045/50684 as well as on ...

HOUSTON, TX, June 03, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the "Company" or "Nexalin") (NASDAQ:NXL, NXLIW))) announces that the U.S. Food and Drug Administration (FDA) has provided feedback and reached consensus on the design for its planned clinical studies in anxiety and insomnia for its new Gen-3 HALO Clarity™ ("HALO"), a non-invasive, Deep Intracranial Frequency Stimulation (DIFS™) headset device designed to address the global mental health epidemic. After the studies are completed and eva ...

HOUSTON, TX, May 22, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the "Company" or "Nexalin") (NASDAQ:NXL, NXLIW))) is pleased to announce its new division, Nexalin America, has been selected to join the National Traumatic Brain Injury (TBI) Registry Coalition ("Coalition"). This esteemed coalition represents a unified alliance of both private sector entities and non-profit organizations committed to fostering the development of a national TBI registry. The Coalition is dedicated to advancing researc ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______. Commission file number: 001-41507 NEXALIN TECHNOLOGY, INC. (Exact name of Registrant as specified in its charter) Delaware 27-5566468 (State or other ...

HOUSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the "Company" or "Nexalin") (NASDAQ:NXL, NXLIW))) is pleased to invite investors to a webinar on May 23, 2024, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Nexalin CEO Mark White, who will share insight into the Company's growing clinical data supporting its non-invasive, frequency-based deep brain stimulation device, as well as progress on its new Gen-3 HALO™ Clarity & Virtual Clinic model. A live Q&A se ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______. Commission file number: 001-41507 NEXALIN TECHNOLOGY, INC. (Exact name of Registrant as specified in its charter) Delaware 27-5566468 (State or other juris ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______. Commission file number: 001-41507 NEXALIN TECHNOLOGY, INC. (Exact name of Registrant as specified in its charter) Delaware 27-5566468 (State or ot ...